Abstract 377P
Background
Human papillomavirus (HPV) associated oropharyngeal squamous cell cancers (OPSCC) are known to have better treatment response and outcome compared with HPV -negative ones. Testing for p16 expression is used as a surrogate for HPV testing. While p16- positive tumours comprise of majority of OPSCC in Western population, p16 -positive tumours in Asian population have remained low.
Methods
Data of Indian patients treated at a single institute between 2016 -2023 was ambispectively analyzed for rate of p16 positivity and clinical outcomes. Staining of ≥70% was considered positive for p16. Data entry and analysis was done using IBM SPSS Statistics v21.0.
Results
Between February 2016 – June 2023, 114 patients were treated, of which 106 had SCC. Majority subsites were tonsil (50, 47.2%), base of tongue (30, 28.3%), and soft palate (15, 14.2%). Testing for p16 was done in 66 patients (62%), of which 19 were p16-positive. Smoking history was noted in 36 patients (34%). Treatment modalities were CTRT for 74 patients (69.8%) and RT alone for 32 (30.2%). IMRT was utilized for majority patients (97, 91.5%). Chemotherapeutic agents were cisplatin for 61 (82.4%, 6 (9.8%) shifted to carboplatin) [3 weekly-9, weekly-52], carboplatin 11 (15%) and cetuximab 2 (3%). Treatment was completed by 101 patients (95.3%) [2 discontinued treatment, 3 died before treatment completion due to non-oncologic causes]. At 3 months, response assessment was done for 94 patients, of which 74 (78.7%) had complete response [14/15 (93.3%) p16-positive, 31/41 (75.6%) p16-negative]; 7 patients (7.4%) had incomplete response while 13 (13.8%) progressed. At median follow-up of 23 months (IQR 11–42); 90 patients were alive, 72 (71.3%) had disease under control. Relapse was seen in 9 patients (p16-positive – 0, p16-negative – 4, untested – 5). Median progression free survival was 17 months (IQR 5-37 months).
Conclusions
While p16 positivity amongst Indian OPSCC patients remains lower than Western counterparts, p16 -positive OPSCC have shown favorable response rates in Indian patients. Association of p16 positivity with improved response rates and fewer relapses in the Indian population warrants investigation in a larger randomized trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amrita Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract